Table 4.
|
Emotional |
Health |
Social |
Intimate |
Stigma |
Body |
Phys. Health & Symptoms |
Treatment Impact^ |
Global |
|
---|---|---|---|---|---|---|---|---|---|---|
|
Distress |
Concerns |
Relationships |
Relationships |
|
Changes |
|
|
|
|
7-factor^ | 8-factor | |||||||||
All patients |
|
|||||||||
Mean (SE) |
64.89 (2.63) |
54.90 (2.64) |
72.55 (2.58) |
51.63 (2.98) |
43.32 (3.10) |
66.48 (2.58) |
71.36 (2.14) |
- |
60.62 (2.01) |
- |
Treated patients |
|
|||||||||
Mean (SE) |
65.16 (2.88) |
57.69 (2.80) |
73.41 (2.79) |
52.01 (3.17) |
46.66 (3.40) |
66.52 (2.73) |
71.05 (2.27) |
81.08 (1.63) |
61.66 (2.21) |
64.07 (2.06) |
Sociodemographic factors | ||||||||||
Male gender |
+8.18 (7.43) |
+13.56 (7.36) |
+2.01 (7.33) |
-9.81 (8.41) |
+9.77 (8.71) |
+4.18 (7.32) |
+3.09 (6.05) |
+7.36 (4.86) |
+4.29 (5.67) |
+4.50 (6.18) |
Transmission (ref: heterosexual/unknown) | ||||||||||
IDU |
+11.61 (11.65) |
+14.29 (11.65) |
-0.89 (11.49) |
+2.28 (13.14) |
+27.39 (13.43)* |
+1.64 (11.49) |
+1.29 (9.48) |
+3.46 (6.77) |
+8.51 (8.89) |
+7.60 (8.57) |
MSM |
+3.51 (5.49) |
+3.17 (5.49) |
-2.28 (5.42) |
-8.60 (6.19) |
+8.41 (6.36) |
+2.56 (5.42) |
-3.01 (4.47) |
+4.34 (3.46) |
+0.82 (4.21) |
+2.20 (4.41) |
Caucasian race |
+11.38 (6.33) |
+18.93 (6.16)† |
+4.84 (6.29) |
-2.75 (7.29) |
+5.98 (7.52) |
+10.87 (6.22) |
+4.29 (5.20) |
+11.34 (4.04)† |
+7.52 (4.84) |
+9.16 (5.23) |
Age >45 years |
+9.04 (5.22) |
+12.21 (5.16)* |
+8.24 (5.13) |
+12.32 (5.87)* |
+11.00 (6.13) |
+5.18 (5.17) |
+6.27 (4.25) |
+9.25 (3.12)† |
+9.02 (3.95)* |
+9.23 (4.02)* |
Living alone |
-0.33 (5.42) |
-2.15 (5.42) |
-11.91 (5.18)* |
-16.74 (5.91)† |
-6.87 (6.36) |
-2.18 (5.32) |
-6.44 (4.35) |
+2.82 (3.38) |
-7.05 (4.1) |
-4.23 (4.29) |
Diagnosed <2 years |
-0.98 (7.27) |
-22.96 (6.91)† |
-2.65 (7.13) |
-3.79 (8.24) |
-18.98 (8.32)* |
+4.54 (7.13) |
+6.54 (5.86) |
-7.04 (5.61) |
-5.34 (5.52) |
-3.04 (7.12) |
Unemployed or |
-23.14 (6.54)‡ |
-5.95 (6.92) |
-20.63 (6.49)† |
-16.88 (7.69)* |
-2.01 (8.14) |
-25.92 (6.3)‡ |
-27.45 (4.91)‡ |
-10.32 (4.07)* |
-17.32 (4.99)‡ |
-16.34 (5.01)† |
sickness benefits |
|
|
|
|
|
|
|
|
|
|
Post-secondary |
+8.44 (5.44) |
+3.18 (5.5) |
-0.4 (5.4) |
-0.8 (6.24) |
-0.65 (6.47) |
+3.03 (5.39) |
+8.22 (4.39) |
-0.92 (3.42) |
+3.2 (4.19) |
+2.17 (4.31) |
education |
|
|
|
|
|
|
|
|
|
|
Substance use over previous 2 weeks | ||||||||||
Tobacco |
+1.1 (5.4) |
+1.49 (5.4) |
-8.65 (5.22) |
+6.95 (6.08) |
+1.75 (6.37) |
-4.62 (5.28) |
-7.68 (4.31) |
-0.81 (3.31) |
-1.69 (4.13) |
-1.09 (4.2) |
Alcohol |
-3.29 (7.46) |
+10.37 (7.41) |
-0.06 (7.33) |
+0.04 (8.47) |
-0.96 (8.76) |
+4.12 (7.32) |
+1.92 (6.06) |
+3.18 (4.44) |
+1.88 (5.69) |
+3.57 (5.6) |
Variance explained by sociodemographic factors | ||||||||||
(proportion) |
18.01% |
22.49% |
19.64% |
20.7% |
18.74% |
20.69% |
32.63% |
20.6% |
22.61% |
21.22% |
Treatment factors | ||||||||||
On ART |
+1.82 (7.47) |
+18.94 (7.24)* |
+5.92 (7.31) |
+2.57 (8.47) |
+22.49 (8.46)† |
+0.27 (7.33) |
-2.08 (6.06) |
- |
+7.00 (5.65) |
- |
Current ART (ref: NNRTI) | ||||||||||
none |
- 3.79 (7.96) |
-19.27 (7.74)* |
-7.50 (7.80) |
-6.44 (8.98) |
-15.00 (8.80) |
-2.09 (7.82) |
-2.99 (6.30) |
- |
-7.95 (6.04) |
- |
PI |
-4.16 (5.75) |
-0.70 (5.59) |
-3.35 (5.63) |
-8.23 (6.48) |
+15.71 (6.37)* |
-3.86 (5.65) |
-10.76 (4.55)* |
-9.93 (3.10)† |
-1.99 (4.37) |
-2.97 (4.13) |
Time on HAART |
+0.23 (0.5) |
+1.38 (0.47)† |
-0.07 (0.49) |
-0.04 (0.56) |
+1.44 (0.57)* |
-0 (0.48) |
-0.12 (0.4) |
+0.36 (0.28) |
+0.43 (0.38) |
+0.42 (0.36) |
(per year) ^ |
|
|
|
|
|
|
|
|
|
|
ART pill burden |
-2.78 (2) |
-0.68 (1.96) |
-2.06 (1.94) |
-3.74 (2.18) |
+3.06 (2.36) |
-2.12 (1.9) |
-3.06 (1.55) |
-3.36 (1.08)† |
-1.56 (1.54) |
-1.78 (1.43) |
(per tablet/day) ^ |
|
|
|
|
|
|
|
|
|
|
ART non-adherent^ |
-2.48 (7.16) |
+2.13 (6.96) |
-3.26 (6.93) |
-7.21 (7.84) |
-2.8 (8.4) |
-1.57 (6.79) |
-6.58 (5.58) |
-9.22 (3.91)* |
-2.95 (5.46) |
-3.72 (5.07) |
On non-ART |
-8.00 (5.41) |
-2.57 (5.47) |
-6.05 (5.34) |
-6.45 (6.17) |
+8.08 (6.38) |
-11.07 (5.26)* |
-12.39 (4.26)† |
-1.19 (3.34) |
-5.35 (4.14) |
-4.61 (4.18) |
medication |
|
|
|
|
|
|
|
|
|
|
Variance explained by treatment factors | ||||||||||
(proportion) |
8.33% |
20.27% |
4.02% |
5.39% |
17.01% |
6.51% |
14.28% |
26.55% |
10.18% |
10.18% |
Biological factors |
|
|
|
|
|
|
|
|
|
|
Body mass index |
|
|
|
|
|
|
|
|
|
|
(per unit) |
-0.01 (0.58) |
-0.35 (0.58) |
-0.29 (0.57) |
+0.20 (0.66) |
+0.02 (0.68) |
+0.08 (0.57) |
-0.18 (0.47) |
+0.16 (0.35) |
-0.07 (0.44) |
-0.01 (0.44) |
CD4 count (per 100 |
|
|
|
|
|
|
|
|
|
|
T cells) |
+0.25 (0.82) |
+1.50 (0.81) |
+0.30 (0.81) |
+1.90 (0.91)* |
+0.22 (0.97) |
+0.80 (0.80) |
+0.42 (0.66) |
+0.88 (0.47) |
+0.81 (0.62) |
+0.84 (0.60) |
Detectable viral |
|
|
|
|
|
|
|
|
|
|
load |
-9.13 (6.08) |
-17.09 (5.92)† |
-10 (5.95) |
-6.36 (6.94) |
-13.05 (7.10) |
-5.94 (6.01) |
-0.87 (4.99) |
-10.52 (4.61)* |
-8.79 (4.6) |
-10.96 (5.86) |
Variance explained by biological factors | ||||||||||
(proportion) |
2.99% |
11.15% |
3.31% |
4.57% |
3.47% |
2.07% |
2.49% |
10.00% |
4.80% |
5.51% |
Clinical factors |
|
|
|
|
|
|
|
|
|
|
Depressive |
-27.84 (5.41)‡ |
-11.26 (5.95) |
-19.64 (5.63)‡ |
-20.76 (6.51)† |
+4.91 (7.12) |
-17.22 (5.69)† |
-24.26 (4.27)‡ |
-6.49 (3.67) |
-16.48 (4.29)‡ |
-16.42 (4.29)‡ |
Other comorbidity |
-10.5 (5.21)* |
+0.27 (5.32) |
-3.97 (5.2) |
-3.95 (6.02) |
+9.49 (6.2) |
-7.59 (5.16) |
-8.61 (4.23)* |
-3.35 (3.27) |
-3.35 (4.06) |
-4.35 (4.14) |
Symptoms |
|
|
|
|
|
|
|
|
|
|
Sexual dysfunction |
-26.02 (5.57)‡ |
-22.06 (5.75)‡ |
-6.69 (6.00) |
-23.14 (6.58)‡ |
-12.38 (7.11) |
-14.88 (5.85)* |
-23.6 (4.40)‡ |
-7.86 (3.73)* |
-18.29 (4.31)‡ |
-16.03 (4.49)‡ |
Gastrointestinal |
-6.73 (1.53)‡ |
-3.99 (1.63)* |
-4.2 (1.59)† |
-5.38 (1.82)† |
-0.31 (1.97) |
-5.63 (1.54)‡ |
-8.57 (1.05)‡ |
-3.3 (0.94)‡ |
-4.95 (1.18)‡ |
-5.06 (1.15)‡ |
(per number) |
|
|
|
|
|
|
|
|
|
|
Malaise (per |
-8.11 (1.58)‡ |
-4.75 (1.71)† |
-6.44 (1.62)‡ |
-4.28 (1.97)* |
+0.17 (2.09) |
-8.29 (1.53)‡ |
-9.18 (1.11)‡ |
-2.21 (1.12) |
-5.95 (1.22)‡ |
-5.84 (1.3)‡ |
number) |
|
|
|
|
|
|
|
|
|
|
Morphological |
-4.71 (1.36)‡ |
-2.2 (1.42) |
-2.75 (1.38)* |
-5.29 (1.54)‡ |
-1.04 (1.68) |
-4.81 (1.33)‡ |
-4.97 (1.05)‡ |
-1.76 (0.84)* |
-3.65 (1.03)‡ |
-3.66 (1.01)‡ |
(per number) |
|
|
|
|
|
|
|
|
|
|
Other (per number) |
-8.39 (2.5)† |
-4.6 (2.6) |
-5.32 (2.53)* |
-4.34 (2.96) |
-0.8 (3.15) |
-11.06 (2.34)‡ |
-9.17 (1.93)‡ |
-2.48 (1.58) |
-6.71 (1.93)‡ |
-7.01 (1.91)‡ |
Variance explained by clinical factors | ||||||||||
(proportion) |
37.25% |
19.37% |
19.68% |
21.82% |
6.7% |
29.97% |
62.04% |
14.2% |
31.92% |
33.31% |
Variance explained by all factors | ||||||||||
(proportion) | 63.64% | 49.81% | 37.24% | 46.31% | 33.07% | 41.26% | 75.36% | 47.83% | 53.01% | 55.4% |
^Analysis restricted to treated patients only.
P-values: ‡ P<0.001; † 0.001≤P<0.01; * 0.01≤ P<0.05.